The drug, shown to be almost as effective as opioids for short-term pain, is the first fundamentally new kind of painkiller ...
This milestone marks a breakthrough after unsuccessful attempts to develop painkillers without the addictive potential of ...
The US Food and Drug Administration (FDA) has approved Vertex Pharmaceuticals’ oral Journavx (suzetrigine) to treat adults ...
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that the U.S. Food and Drug Administration (FDA) has ...
Despite high demand for an option like Journavx, doctors fear the drug’s price could be a major hangup for insurers, ...
Vertex has gained the FDA's approval for its non-addictive pain med Journavx, which becomes the first significant innovation ...
The FDA has approved Journavx, a new non-opioid pain medication designed to reduce addiction and overdose risks.
Federal officials on Thursday approved a new type of pain drug designed to eliminate the risks of addiction and overdose ...
The FDA approved Vertex Pharmaceuticals’ Journavx, a new non-opioid pain pill for short-term pain. While safer than opioids, ...
The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
On Thursday, in a major step forward in pain management, the U.S. Food and Drug Administration has approved a new nonopioid ...
Vertex Pharmaceuticals Inc. (VRTX) has secured FDA approval for Suzetrigine, an oral, non-opioid, highly selective NaV1.8 pain signal ...